[Specific immunotherapy]

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

[Specific immunotherapy]

Arch Pediatr. 1999;6 Suppl 1:108S-113S. Unique Identifier : AIDSLINE MED/99207659
Just J; Houzel-Charavel A; Grimfeld A; Polyclinique de pneumologie pediatrique, hopital d'Enfants; Armand-Trousseau, Paris, France.

Abstract: Increase of the prevalence of allergy these last 20 years is in part secondary to the modification of the allergenic charge of our environment. The specific immunotherapy (SIT) is the only etiologic treatment of the allergic disease and numbers of authors believe that, for the future, this treatment could change the natural history of the respiratory allergy, provided that it is realised early in the first years of life. Several experimental studies show that the process of the SIT could be the restoration of the Th1 cell/Th2 cell balance which is reversed in allergies. However, indications of SIT have to be carefully selected. The ideal indication is the single sensitized asthma, and treatment has to be started in the first years of life, at the onset of the asthmatic disease, before a definitive remodelling of the respiratory airways induced by inflammation. Subcutaneous SIT is for the moment the only effective route confirmed by several controlled trials, in particular for grass pollens, possibly for house dust, pet danders and mite allergens. Risk of syndromic effects, present all the time of the SIT protocol, can be prevented by rigorous use of the SIT according to the European consensus. The advent of recombinant allergens, in particular by complementary DNA (cDNA) modified by site-directed mutagenesis, could tip the immune response to a Th-1 like response instead of a Th-2 like response (IgE mediated) and result in a better tolerated and more efficacy immunomodulation.

Keywords: JOURNAL ARTICLE Age Factors Allergens/ADMINISTRATION & DOSAGE/IMMUNOLOGY Asthma/IMMUNOLOGY/THERAPY Child Child, Preschool Comparative Study *Desensitization, Immunologic/ADVERSE EFFECTS/METHODS English Abstract Human IgE/IMMUNOLOGY Infant Odds Ratio Respiratory Hypersensitivity/IMMUNOLOGY/*THERAPY Th1 Cells/IMMUNOLOGY Th2 Cells/IMMUNOLOGY
990730
A9971194

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .